Non classé | Canaud Lab

Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)

Oct 19, 2021 | Non classé

PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24 weeks, 38% of patients achieved ≥20% reduction in the volume of the PROS...

ESMO 2021 – Real-life data demonstrating the efficacy of alpelisib in dysharmonious hypergrowth syndromes (called PROS) linked to activating mutations of the PIK3CA pathway

Oct 19, 2021 | Non classé

The team of Professor Guillaume Canaud of the adult nephrology-renal transplantation department of the Necker-Enfants Malades AP-HP hospital, has been very involved for several years in the management of patients with dysharmonious hypergrowth syndrome (PIK3CA-Related...

New therapeutic perspectives for patients with lymphatic abnormalities linked to a mutation in the PIK3CA gene

Oct 6, 2021 | Non classé

The team from the adult nephrology-renal transplantation department of the Necker-Enfants Malades AP-HP hospital, Inserm and the University of Paris has carried out work, coordinated by Prof. Guillaume Canaud, which opens up new perspectives. therapies for patients...